Overview
Global Bowel Management Systems Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
Bowel management systems (BMS) are temporary containment devices, indicated for bedridden or immobilised incontinent patients, with little or no bowel control, who have a liquid or semi-liquid stool. They are also indicated for patients with severe burns to manage their bowel function, promote healing of genital, perineal or anal skin grafts and maintain infection control following plastic surgery.
A bowel management system for the control of faecal incontinence should only be inserted once all other faecal incontinence management alternatives have been considered. The use of a bowel management system must be agreed upon with the medical team in charge of the patient’s care following a holistic assessment of
the patient which has taken into consideration: infection control, risk of device-related skin breakdown, privacy and dignity, and contraindications for use.
In addition to preventing the spread of infection, a bowel management system can potentially prevent faecal bacterial contamination of urinary, intravenous and arterial catheters located in the groin area, causing local and systemic infection.
Market Dynamics: Drivers and Restraints
Rise in the technological advancements and product launches
The rise in the advancements in bowel management systems and novel product launches by key players will further drive the market growth during the forecast period.
For instance, in April 2023, NHS foundation trust owned digital health company health call launched a self-referral platform for bladder and bowel issues, allowing users to self-refer to services from the trust website without seeing their GP. The platform simplifies the process of seeking help and support, allowing users to give precise, factual referrals that are easier to triage by the trust.
The platform launched in 2023, has significantly improved triage and sped up referrals, allowing patients to access the service 24/7. Th,e solution also provides a clear audit trail for referrals and speeds up the process. Technology is playing a growing role in bladder and bowel care, with AI devices being trailed by nine NHS trusts and UK start-up Motilent receiving funding from the National Institute for Health and Care Research.
Moreover, in February 2022, Coloplast, one of the world’s leading manufacturers of stoma care products launched its latest product innovation, the SenSura Mio in Singapore this year. Singapore is the first country in Southeast Asia that launch SenSura Mio which aims to improve the quality of life of ostomates, or people who have gone through ostomy and are now living with stoma.
Furthermore, the rise in the prevalence of inflammatory bowel diseases, the increasing geriatric population, the launch of various bowel management products, recent and new potential approvals, and Favorable reimbursement policies, will further drive the market growth during the forecast period.
Market Dynamics: Restraint
Patient preference for non-invasive clinical management of Fecal incontinence. Currently, Fecal incontinence can be managed invasively (surgically) or non-invasively. Standard modes of surgical treatment include the injection of biomaterials into the anal canal, radiofrequency treatment of the anal canal, surgical repair of anal muscle injuries, sacral nerve stimulation, artificial bowel sphincter, muscle transposition to reinforce the anal sphincter and the creation of a stoma. These often require long-term patient rehabilitation and also it is highly inconvenient and even severely painful.
Also, lack of awareness, regulatory concerns, and concerned side effects are also the factors that hamper the market growth rate during the forecast period.

Segment Analysis
The global bowel management systems is segmented based on product type, application, patient type, end-user and region.
The colostomy bags from the product type segment accounted for approximately 41.2% of the market share
The colostomy bags from the product type segment accounted for 41.2% and it is expected to be dominated during the forecast period. A colostomy bag is a plastic bag that collects faecal matter, also called stool or poop, from the digestive tract through an opening in the abdominal wall called a stoma. Doctors attach a bag to the stoma following a colostomy operation.
A colostomy bag, also called a stoma bag or ostomy bag, is a small, waterproof pouch used to collect waste from the body. During a surgical procedure known as a colostomy, an opening called a stoma or ostomy is formed between the large intestine (colon) and the abdominal wall. This allows waste products to be excreted through the opening in the abdominal wall rather than via the colon through the rectum and anus.
For instance, in December 2021, Coloplast launched a clinical trial to test the effect of its ostomy product, Heylo, a product that uses sensors to warn patients with colostomy bags about leakage and advise them about how to prevent it. Thus, the above-mentioned factors are expected to drive the growth of the studied segment during the forecast period.

Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to factors such as the rising prevalence of colorectal cancer and the growing geriatric population. Additionally, increased patient awareness, rising adoption rates of intestinal management systems, increasing investments in product development, excellently established healthcare infrastructure, and strong acceptance of developed products are some of the key factors ensuring the region’s dominance.
For instance, in May 2023 Advanced Medical Balloons GmbH (formerly Creative Balloons GmbH), a specialist in medical technology from Waghaeusel near Heidelberg, stated that the company is expanding its intensive care business to the United States.
This is based on the approval which has recently been granted by the U.S. Food and Drug Administration (FDA) for their innovative catheter system hygh-tec. The novel faecal management system hygh-tec provides maximum seal and prevention of faecal leakage in patients receiving intensive care.
Moreover, in July 2021 Trio Healthcare secured a second round of funding from US specialist finance company, SWK Holdings Corporation. The funding, approximately $10m in total, will support Trio’s R&D and manufacturing as it scales up operations to support a large-scale global roll-out of Trio’s world-first stoma bag, GeniiTM

COVID-19 Impact Analysis
COVID 19 had a substantial impact on bowel management systems. Amidst the outbreak of the COVID-19 pandemic, there has been a rise in other health complications that rose with COVID-19 infections. According to a report by the surveillance epidemiology of coronavirus Under Research Exclusion (SECURE-IBD) database published in January 2022 mentioned that adverse COVID-19 outcomes were associated with age and other co-morbidities among patients with inflammatory bowel disease (IBD).

Competitive Landscape
The major global players in the bowel management systems market include Becton, Dickinson and Company, Coloplast Pty Ltd., ConvaTec Group plc., B Braun SE., Consure Medical Pvt. Ltd., GBUK Group Ltd., Wellandmedical, Wellspect, ProSys International Ltd Qufora and among others.
Key Developments
? In April 2022, Microbiotica received project funding from the crohn’s and colitis foundation as a part of their inflammatory bowel disease ventures program for the development of therapies to treat inflammatory bowel disease.
? In November 2021, Medtronic plc, a global leader in healthcare technology, stated that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its PillCam Small Bowel 3 system for remote endoscopy procedures. The PillCam SB3 @HOME program combines Medtronic’s PillCam technology with Amazon logistics, a combination intended to ensure both timely and accurate results for patients from the comfort of their homes.
? In May 2021, Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, stated European CE Mark approval of its second-generation Axonics r-SNM implantable neurostimulator (INS) and wireless patient remote control with SmartMRI technology.
Why Purchase the Report?


    • To visualize the global bowel management systems market segmentation-based product type, application, patient type, end-user and region as well as understand key commercial assets and players.
    • Identify commercial opportunities by analysing trends and co-development
    • Excel data sheet with numerous data points of bowel management systems market-level with all segments.
    • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
    • Product mapping available as excel consisting of key products of all the major players.


The global bowel management systems market report would provide approximately 69 tables, 70 figures, and 185 Pages.
Target Audience 2023


  • • Manufacturers/ Buyers
    • Industry Investors/Investment Bankers
    • Research Professionals
    • Emerging Companies